RxDoctor Payments Data

Robert Kincaid, DO

Family Medicine · Pace, FLNPI 1386650406

Payments from drug & device makers

$510in general payments, 2019–2025

Across 35 payments — averaging $14.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$99
  • Novo Nordisk$92
  • Lilly USA, LLC$65
  • Abbott$41
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$39
  • Pfizer$32
  • plus $143 from 7 others

What the payments were for

  • Food & beverage$510100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$510 in reported general payments places this provider in the 50th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$187,520
Medicare patients
442
Services billed
1,956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide91$139,853
OzempicSemaglutide95$119,354
Synjardy XrEmpagliflozin/Metformin Hcl43$46,132
MounjaroTirzepatide38$38,211
EliquisApixaban38$35,762
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$27,628
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog28$23,149
Janumet XrSitagliptin Phos/Metformin Hcl33$21,764
Breo ElliptaFluticasone/Vilanterol29$19,732
JardianceEmpagliflozin21$19,516
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$16,579
Xigduo XrDapaglifloz Propaned/Metformin14$14,677
RybelsusSemaglutide12$11,437
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$9,186
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$6,419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$65$178,064129 claims
Novo NordiskOzempic, Rybelsus$92$130,791107 claims
Boehringer IngelheimSynjardy Xr, Jardiance$22$65,64864 claims
PfizerEliquis, Premarin$32$40,36649 claims
GSKBreo Ellipta, Trelegy Ellipta$29$36,31143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Pace

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →